98%
921
2 minutes
20
Pancreatic ductal adenocarcinoma (PDAC) is characterized by extensive desmoplasia, which challenges the molecular analyses of bulk tumor samples. Here we FACS-purified epithelial cells from human PDAC and normal pancreas and derived their genome-wide transcriptome and DNA methylome landscapes. Clustering based on DNA methylation revealed two distinct PDAC groups displaying different methylation patterns at regions encoding repeat elements. Methylation tumors are characterized by higher expression of endogenous retroviral transcripts and double-stranded RNA sensors, which lead to a cell-intrinsic activation of an interferon signature (IFNsign). This results in a protumorigenic microenvironment and poor patient outcome. Methylation/IFNsign and Methylation/IFNsign PDAC cells preserve lineage traits, respective of normal ductal or acinar pancreatic cells. Moreover, ductal-derived / mouse PDACs show higher expression of IFNsign compared with acinar-derived counterparts. Collectively, our data point to two different origins and etiologies of human PDACs, with the aggressive Methylation/IFNsign subtype potentially targetable by agents blocking intrinsic IFN signaling. SIGNIFICANCE: The mutational landscapes of PDAC alone cannot explain the observed interpatient heterogeneity. We identified two PDAC subtypes characterized by differential DNA methylation, preserving traits from normal ductal/acinar cells associated with IFN signaling. Our work suggests that epigenetic traits and the cell of origin contribute to PDAC heterogeneity..
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216338 | PMC |
http://dx.doi.org/10.1158/2159-8290.CD-20-1202 | DOI Listing |
bioRxiv
August 2025
Department of Dermatology, School of Medicine, University of California San Diego.
Oncogene targeted cancer therapies can provide deep responses but frequently suffer from acquired resistance. Therapeutic approaches to treat tumours which have acquired drug resistance are complicated by continual tumour evolution and multiple co-occurring resistance mechanisms. Rather than treating resistance after it emerges, it may possible to prevent it by inhibiting the adaptive processes which initiate resistance but these are poorly understood.
View Article and Find Full Text PDFElife
August 2025
Tumor Virus RNA Biology Section, HIV Dynamics and Replication Program, CCR/NCI/NIH, Frederick, United States.
Increased expression of lnc-FANCI-2, a newly discovered long noncoding RNA, is associated with cervical lesion progression from cervical intraepithelial neoplasia stage 1 (CIN1, low grade), CIN2-3 (high grade), to cervical cancer. Viral oncoprotein E7 of high-risk human papillomaviruses (HR-HPVs) and host transcription factor YY1 are two major factors promoting lnc-FANCI-2 expression. Using CRISPR-Cas9 technology, we knocked out the expression of in the HPV16-positive cervical cancer cell line, CaSki cells.
View Article and Find Full Text PDFAntioxidants (Basel)
August 2025
College of Traditional Chinese Veterinary Medicine, Hebei Agricultural University, No. 2596 Lekai South Street, Baoding 071000, China.
polysaccharide (DSPS) is the main natural compound extracted from the traditional Chinese herb . Although DSPS is well-known for its antioxidant and anti-inflammatory properties, its impact on aflatoxin B1 (AFB1)-induced damage has not been explored. This study aims to investigate the potential protective mechanisms of DSPS against AFB1-induced liver damage and immune disorders.
View Article and Find Full Text PDFBiomolecules
August 2025
Research Group Genetics, Reproduction and Development, Faculty of Medicine and Pharmacy, Brussels Health Campus, Vrije Universiteit Brussel (VUB), Laarbeeklaan 103, 1090 Brussels, Belgium.
C-C motif chemokine receptor-like 2 (CCRL2) is an atypical chemokine receptor (ACKR) that binds chemerin with high affinity but lacks classical G protein-coupled signaling. Instead, it functions as a non-signaling presenter of chemerin to CMKLR1-expressing cells, modulating antitumor immunity. CCRL2 is highly expressed in the tumor microenvironment and various human cancers, and its expression has been linked to delayed tumor growth in mouse models, primarily through the chemerin/CMKLR1 axis.
View Article and Find Full Text PDFCancer Immunol Immunother
August 2025
Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, 03722, Republic of Korea.
Background: The therapeutic efficacy of oncolytic vaccinia virus (JX-594) has been demonstrated in metastatic clear cell renal cell carcinoma (ccRCC); however, only selected patients respond, and there are no predictive biomarkers for therapeutic response. We aimed to identify predictive biomarkers for JX-594 treatment and elucidate the underlying mechanisms.
Methods: Four cell line-derived xenograft (CDX) models were developed using representative ccRCC cell lines harboring common mutations.